Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial

Veure altres versions (1)

<strong>Background<br></strong> Methotrexate is the first-line treatment for immune-mediated inflammatory diseases and reduces vaccine-induced immunity. We evaluated if a 2-week interruption of methotrexate treatment immediately after COVID-19 booster vaccination improved antibody...

Descripció completa

Dades bibliogràfiques
Autors principals: Abhishek, A, Peckham, N, Pade, C, Gibbons, JM, Cureton, L, Francis, A, Barber, V, Williams, JAE, Appelbe, D, Eldridge, L, Julier, P, Altmann, DM, Bluett, J, Brooks, T, Coates, LC, Rombach, I, Semper, A, Otter, A, Valdes, AM, Nguyen-Van-Tam, JS, Williams, HC, Boyton, RJ, McKnight, Á, Cook, JA
Altres autors: VROOM study investigators
Format: Journal article
Idioma:English
Publicat: Elsevier 2023

Ítems similars